54 results
SC 14D9
SGTX
Sigilon Therapeutics Inc
13 Jul 23
Tender offer solicitation
8:18am
Product conducted by Parent in any country that satisfies the requirements of 21 CFR 312.21(a) and is designed to assess the safety of such Product … or commercialization in light of issues of safety and efficacy, product profile, the competitiveness of the marketplace, the proprietary position of the compound
SC TO-T
EX-99
SGTX
Sigilon Therapeutics Inc
13 Jul 23
Third party tender offer statement
8:01am
the requirements of 21 CFR 312.21(a) and is designed to assess the safety of such Product in patients.
“Pivotal Trial” means a human clinical trial … or commercialization in light of issues of safety and efficacy, product profile, the competitiveness of the marketplace, the proprietary position
8-K
EX-10.1
SGTX
Sigilon Therapeutics Inc
29 Jun 23
Lilly to Acquire Sigilon Therapeutics
7:03am
which is of similar market potential at a similar stage of development or commercialization in light of issues of safety and efficacy, product profile … in any country that satisfies the requirements of 21 CFR 312.21(a) and is designed to assess the safety of such Product in patients.
“Pivotal Trial
8-K
EX-2.1
SGTX
Sigilon Therapeutics Inc
29 Jun 23
Lilly to Acquire Sigilon Therapeutics
7:03am
of absence (including the federal Emergency Family and Medical Leave Expansion Act), workers’ compensation, safety and health, immigration and work … of safety or efficacy or material regulatory compliance of any Product, including any Product recall, removal, suspension, withdrawal, field
8-K
EX-99.1
oin5u
9 May 23
Sigilon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
7:37am
8-K
EX-99.1
fwn 20oic58
10 Nov 22
Sigilon Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
7:37am
8-K
EX-99.2
fvro9h 3lys
10 Nov 22
Sigilon Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
7:37am
8-K
EX-99.1
6qnwdl82485r bqi
11 Oct 22
Regulation FD Disclosure
8:30am
8-K
EX-99.1
kjg8mn0mjug j8
4 Aug 22
Sigilon Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
4:45pm
8-K
EX-99.1
w8zc rlahi20gum
12 May 22
Sigilon Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
4:16pm
S-3
EX-1.2
17khm257s6ssf
14 Apr 22
Shelf registration
4:34pm
8-K
EX-99.1
jydsm7anw 23hr4xz
14 Mar 22
Sigilon Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
4:31pm
8-K
EX-99.2
ejpdzo3 8p7z978r
14 Mar 22
Sigilon Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
4:31pm